(CHRS) Coherus BioSciences - Overview
Stock: Biosimilar, Immunotherapy, Oncology, Antibody, Cytokine
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 93.5% |
| Relative Tail Risk | -8.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.12 |
| Alpha | 58.44 |
| Character TTM | |
|---|---|
| Beta | 1.368 |
| Beta Downside | 1.951 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.93% |
| CAGR/Max DD | -0.38 |
Description: CHRS Coherus BioSciences January 18, 2026
Coherus Oncology, Inc. (NASDAQ: CHRS) is a U.S.-based biopharma that focuses on developing and commercializing immunotherapies for cancer, alongside a portfolio of biosimilars targeting both oncology and inflammatory indications. The firm rebranded from Coherus BioSciences to Coherus Oncology in May 2025 and is headquartered in Redwood City, California.
The pipeline includes UDENYCA (a Neulasta biosimilar), LOQTORZI (a next-generation PD-1 inhibitor), and several investigational monoclonal antibodies such as CHS-114 (afucosylated IgG1 targeting a Treg-associated chemokine receptor) and CHS-1000 (anti-ILT4). Additional assets comprise GSK4381562 (CD112R antibody), YUSIMRY (a Humira biosimilar for multiple TNF-driven diseases), and CIMERLI (a Lucentis biosimilar for retinal disorders). Coherus leverages a network of collaborations-including co-development with Junshi Biosciences on toripalimab and licensing deals with Bioeq, Genentech, Novartis, and GSK-to broaden market reach and share development risk.
As of Q3 2024, the company reported cash and equivalents of roughly $220 million, providing runway into 2026 under current burn rates, while R&D spend has averaged 30 % of revenue-a typical ratio for late-stage biotech firms. The U.S. biosimilar market is projected to grow at a CAGR of ~12 % through 2028, driven by payer pressure and patent expirations, which could underpin upside for UDENYCA and YUSIMRY if FDA approvals are secured. Investors should monitor the FDA decision timeline for LOQTORZI and the commercial launch metrics for UDENYCA, as these catalysts will materially affect valuation. For a deeper quantitative assessment, a quick look at ValueRay’s analyst models may help surface hidden risk/reward dynamics.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: 155.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA -5.18 > 1.0 |
| NWC/Revenue: 104.3% < 20% (prev 32.00%; Δ 72.31% < -1%) |
| CFO/TA -0.17 > 3% & CFO -90.2m > Net Income 155.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (116.2m) vs 12m ago 0.88% < -2% |
| Gross Margin: 47.79% > 18% (prev 0.41%; Δ 4739 % > 0.5%) |
| Asset Turnover: 16.36% > 50% (prev 45.46%; Δ -29.10% > 0%) |
| Interest Coverage Ratio: -14.50 > 6 (EBITDA TTM -171.3m / Interest Expense TTM 12.1m) |
Altman Z'' -12.99
| A: 0.17 (Total Current Assets 461.0m - Total Current Liabilities 373.8m) / Total Assets 516.5m |
| B: -2.60 (Retained Earnings -1.35b / Total Assets 516.5m) |
| C: -0.34 (EBIT TTM -175.4m / Avg Total Assets 510.8m) |
| D: -3.14 (Book Value of Equity -1.35b / Total Liabilities 428.7m) |
| Altman-Z'' Score: -12.99 = D |
Beneish M -1.46
| DSRI: 3.46 (Receivables 250.5m/198.8m, Revenue 83.6m/229.6m) |
| GMI: 0.85 (GM 47.79% / 40.63%) |
| AQI: 0.40 (AQ_t 0.10 / AQ_t-1 0.26) |
| SGI: 0.36 (Revenue 83.6m / 229.6m) |
| TATA: 0.47 (NI 155.0m - CFO -90.2m) / TA 516.5m) |
| Beneish M-Score: -1.46 (Cap -4..+1) = D |
What is the price of CHRS shares?
Over the past week, the price has changed by -0.93%, over one month by +57.35%, over three months by +43.62% and over the past year by +89.38%.
Is CHRS a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CHRS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.8 | 215.4% |
| Analysts Target Price | 6.8 | 215.4% |
| ValueRay Target Price | 2.1 | -2.8% |
CHRS Fundamental Data Overview February 03, 2026
P/E Forward = 41.1523
P/S = 0.9401
P/B = 2.9745
Revenue TTM = 83.6m USD
EBIT TTM = -175.4m USD
EBITDA TTM = -171.3m USD
Long Term Debt = 37.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.79m USD (from shortTermDebt, last quarter)
Debt = 40.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -62.7m USD (from netDebt column, last quarter)
Enterprise Value = 110.1m USD (261.1m + Debt 40.7m - CCE 191.7m)
Interest Coverage Ratio = -14.50 (Ebit TTM -175.4m / Interest Expense TTM 12.1m)
EV/FCF = -1.22x (Enterprise Value 110.1m / FCF TTM -90.2m)
FCF Yield = -81.91% (FCF TTM -90.2m / Enterprise Value 110.1m)
FCF Margin = -107.9% (FCF TTM -90.2m / Revenue TTM 83.6m)
Net Margin = 185.4% (Net Income TTM 155.0m / Revenue TTM 83.6m)
Gross Margin = 47.79% ((Revenue TTM 83.6m - Cost of Revenue TTM 43.6m) / Revenue TTM)
Gross Margin QoQ = 67.84% (prev 66.89%)
Tobins Q-Ratio = 0.21 (Enterprise Value 110.1m / Total Assets 516.5m)
Interest Expense / Debt = 5.71% (Interest Expense 2.33m / Debt 40.7m)
Taxrate = 0.0% (0.0 / 28.5m)
NOPAT = -175.4m (EBIT -175.4m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 1.23 (Total Current Assets 461.0m / Total Current Liabilities 373.8m)
Debt / Equity = 0.46 (Debt 40.7m / totalStockholderEquity, last quarter 87.8m)
Debt / EBITDA = 0.37 (negative EBITDA) (Net Debt -62.7m / EBITDA -171.3m)
Debt / FCF = 0.69 (negative FCF - burning cash) (Net Debt -62.7m / FCF TTM -90.2m)
Total Stockholder Equity = -27.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 30.34% (Net Income 155.0m / Total Assets 516.5m)
RoE = -574.7% (negative equity) (Net Income TTM 155.0m / Total Stockholder Equity -27.0m)
RoCE = -1755 % (out of range, set to none) (EBIT -175.4m / Capital Employed (Equity -27.0m + L.T.Debt 37.0m))
RoIC = -141.4% (out of range, set to none) (NOPAT -175.4m / Invested Capital 124.1m)
WACC = 10.25% (E(261.1m)/V(301.8m) * Re(10.96%) + D(40.7m)/V(301.8m) * Rd(5.71%) * (1-Tc(0.0)))
Discount Rate = 10.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.10%
Fair Price DCF = unknown (Cash Flow -90.2m)
EPS Correlation: 75.72 | EPS CAGR: 140.8% | SUE: 1.65 | # QB: 1
Revenue Correlation: -41.53 | Revenue CAGR: -38.89% | SUE: -0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.27 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.49 | Chg30d=+0.295 | Revisions Net=+0 | Growth EPS=+63.2% | Growth Revenue=+118.9%